Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
about
Historical review of the causes of cancerAdoptive T-cell therapy for fungal infections in haematology patientsAdoptive T-Cell ImmunotherapyUnderstanding the interplay between host immunity and Epstein-Barr virus in NPC patientsT lymphocytes targeting native receptorsEmerging treatment options for nasopharyngeal carcinomaNovel immunotherapies for hematologic malignanciesCellular immunotherapy for pediatric solid tumorsEnhanced response of T cells from murine gammaherpesvirus 68-infected mice lacking the suppressor of T cell receptor signaling molecules Sts-1 and Sts-2Blood disorders typically associated with renal transplantationGetting personal with melanoma.A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.Epstein-Barr virus: the path from association to causality for a ubiquitous human pathogen.T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo.Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disordersGeneration of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.Genetically modified T-cell therapy for osteosarcomaA novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses.Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profileMolecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene TherapyCytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma.Exploiting the curative potential of adoptive T-cell therapy for cancer.Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.Combining drugs and biologics to treat nasopharyngeal cancer.Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.Immunotherapy for EBV-associated malignancies.Biomarkers in T cell therapy clinical trials.Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".Optimization manufacture of virus- and tumor-specific T cellsWill T-cell therapy for cancer ever be a standard of care?Adoptive immunotherapy for cancer.Adoptive immunotherapy for cancer or viruses.Gene-modified cells for stem cell transplantation and cancer therapy.
P2860
Q26767036-707F21D1-3295-4DD5-B8F3-509EC44BDD43Q26781064-A624878F-657D-49C7-8EAE-5914B80B49B4Q26782845-D3697417-66D4-4FB0-8C95-2243346D5DD5Q26823898-A1C65BB0-1637-4B67-8C83-143D4F348284Q26853345-E65C9430-A5AE-4C49-A96C-F153F693707CQ26995560-7C38355B-1F82-4B7F-8934-E93CB9D82E07Q27004436-DC4AEC1A-45CF-450C-80A7-AFF85473D62DQ27014912-C62A3EC3-5680-485A-8A27-D589962F5FC8Q27318672-3AEC2A9B-EB6A-4409-B06C-C47719469204Q33421793-BC7DAD20-ACB9-43A0-A031-C778496E798FQ35091410-D9E93CDC-4E2C-45B9-BF99-BD2589355059Q35121627-C59AC727-EDF5-45B7-8345-DBA7A6960858Q35142912-C2FEE2B0-6517-4419-8C18-C78E47891216Q35236719-E37DDE06-9B2F-4F90-9700-7A6ACB579334Q35483599-0782D71C-931F-4D50-A4F2-7834E2ABE1B5Q35507358-32DCF198-1B8E-4391-8CE0-523963E26427Q35684896-D183899A-1F04-47C0-9AC7-B6651B81D704Q35738744-AAB6A53A-6033-46F2-B028-9698E676CDCDQ35759682-D67CE31E-244E-43F0-95FB-0EDF69C76A20Q35815850-412738E5-8FAE-40A7-BA62-031B47867D81Q35832185-37E23048-398A-4DA3-8A91-45EB4ED461F1Q35857642-818A4AC7-8A6D-4341-BB2C-DAFBA3FE6206Q36198232-3214CD74-2187-48DD-9392-AC81158513C8Q36298938-AF6EF84A-F08F-4FDD-A6BE-50ABBF4179C1Q36687528-B0767980-5FC1-4C89-8D37-178D45EB75A3Q36928580-BB83563E-37D1-4A25-BD4D-F938DB91A775Q37545032-CDD6528A-451E-4645-8C4F-771E17A7FFB1Q37576033-27D5AF79-0CB2-4DA7-AA1D-F6B1249CE9EDQ37690437-2B4FFEF2-FB4C-4A0D-8E45-29E45A0FB545Q37690461-63DE2B2C-883B-457A-88F0-491E1AEF134EQ37705026-3363F4C7-C3D1-4E5D-B12B-DCF51EA9FA98Q37713951-171459EC-7733-4249-823A-DAE2D9D472DCQ37845178-7AA7B82B-AE4F-42C9-B1E5-0CBC2C6C1B8FQ37919589-4795E66E-7D45-416C-AEFA-C31CEAD0D604Q37919880-5F37D856-DD9E-48FD-B4E1-3F4D6148B48CQ37931623-19E96D64-C2CD-4AF4-BFED-6A4B59CB31BEQ38051546-5F37E143-3AE3-4469-848C-6CCBAF9E1C13Q38170496-DD3CFC03-926C-46C2-8012-A00721131B03Q38178359-6A9D3C55-00D1-4C90-981C-2C44D187B52EQ38230157-3866299F-91FB-4FC1-B157-4A7CA30AD121
P2860
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@ast
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@en
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@nl
type
label
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@ast
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@en
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@nl
prefLabel
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@ast
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@en
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@nl
P2093
P2860
P1476
Adoptive transfer of EBV-speci ...... onal nasopharyngeal carcinoma.
@en
P2093
Adrian Gee
Andrea Sheehan
Catherine M Bollard
Chrystal U Louis
Claudia Gerken
Cliona M Rooney
Helen E Heslop
Karin Straathof
M Helen Huls
P2860
P304
P356
10.1097/CJI.0B013E3181F3CBF4
P577
2010-11-01T00:00:00Z